# Avacta Group COVID-19 Antigen Diagnostic Collaboration with Adeptrix

- Link: https://www.directorstalkinterviews.com/avacta-group-covid-19-antigen-diagnostic-collaboration-with-adeptrix/412816847
- Published: 2020-05-01T07:09:23+01:00
- Author: Giles Arbor

**Second partnership to exploit the recently generated Affimer binders to the SARS-
COV-2 virus in a high throughput COVID-19 antigen test**

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)),
the developer of Affimer^(®) biotherapeutics and reagents, has today announced that
it has entered into a collaboration with Adeptrix (Beverly, MA, USA) to develop 
a high throughput COVID-19 antigen test using Adeptrix’s proprietary bead-assisted
mass spectrometry (BAMS™) platform.

Avacta and Adeptrix will collaborate to develop and manufacture an Affimer-based
BAMS coronavirus antigen test that will provide clinicians with a significant expansion
of the available testing capacity for COVID-19 infection in hospitals.

Adeptrix’s novel BAMS platform combines enrichment of the sample to improve sensitivity
with the power of mass-spectrometry to improve specificity. Hundreds of samples 
per day can be analysed by a single technician using BAMS, exceeding the capacity
of single PCR machine, making BAMS a very attractive high throughput technique for
COVID-19 screening in the clinical setting.

The diagnostic test will allow hospitals around the world to utilise their existing
installed base of mass spectrometers that are not currently used for COVID-19 testing,
thus contributing significantly to the increase in global testing capacity. Avacta’s
recently developed Affimer reagents that bind the SARS-COV-2 spike protein will 
be used to provide the capture and enrichment of the virus particle from the sample
which could be saliva, nasopharyngeal swabs or serum.  

Development of a BAMS test capable of diagnosing whether a person has the COVID-
19 infection at any specific moment is a quick process and the companies are aiming
to have a BAMS test ready for clinical validation, regulatory approval and manufacturing
in June. Adeptrix and Avacta are already in discussion with large-scale manufacturing
partners to rapidly deploy this new high throughput test.

Further commercial details are not being disclosed but Avacta will receive a royalty
on the sales of BAMS test kits by Adeptrix.

> **Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: **
> “We are delighted to have established this partnership with Adeptrix in our push
> to develop Affimer -based COVID-19 antigen tests. Jeff and his team are world-
> renowned in the mass spectrometry field, and the BAMS diagnostic platform is highly
> sensitive and specific, giving us great confidence that a high performance COVID-
> 19 antigen test can be developed and launched commercially very quickly.
> We believe that the BAMS test will be hugely attractive as an adjunct to PCR testing
> because it uses laboratory equipment that is already in hospital labs but not 
> currently used for COVID-19 testing so it provides incremental testing capacity.
> A consensus view is building around the world that hundreds of millions of COVID-
> 19 tests are going to be required per month for a long period, and that the disease
> will be endemic after the initial pandemic has passed, meaning that testing for
> COVID-19 is going to be needed for many years.
> I have made it clear that we intend to partner the SARS-COV-2 spike protein Affimer
> reagents with several select companies to support antigen test development on 
> multiple diagnostic test platforms. This will contribute most effectively to the
> urgent need to increase antigen testing capacity globally and maximise the commercial
> return to Avacta. Adeptrix is one example of this and other discussions are underway.
> I look forward very much to further updating the market in the near future.”

> **Dr. Jeffrey C. Silva, Director of Product Development, Adeptrix Corporation 
> commented:**
> “I am pleased to have Avacta recognise the promise of the BAMS technology with
> respect to its sensitivity, accuracy and high throughput capacity. I have worked
> with Affimers previously and have found them to be excellent immunoassay reagents,
> so we are looking forward to quickly implementing the SARS-COV-2 Affimers in a
> BAMS diagnostic test.
> Mass spectrometry can enhance the diagnostic utility of immunoassays, as it is
> capable of monitoring both existing and emerging viral strains by accurately measuring
> the molecular components of the virus. BAMS provides an ideal multiplexing platform
> to obtain higher specificity for monitoring COVID-19 infection.
> We are excited to be working with Avacta to rapidly develop BAMS tests and supply
> them to clinical diagnostic laboratories.”

Share on:
